Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012

JAMA

Volumn 311, Issue 4, 2014, Pages 368-377

  Downing, Nicholas S ^a   Aminawung, Jenerius A ^a   Shah, Nilay D ^c   Krumholz, Harlan M ^a,b   Ross, Joseph S ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892726671     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282034     Document Type: Article

References (31)

1. Schwartz LM, Woloshin S. Communicating uncertainties about prescription drugs to the public: a national randomized trial. Arch Intern Med. 2011;171(16):1463-1468.
2. Zhang J, Zhang H, Yu CH, Li JY, Jiang Y. The attitudes of oncology physicians and nurses toward phase I, II, and III cancer clinical trials. Contemp Clin Trials. 2011;32(5):649-653.
3. Chen DT, Wynia MK, Moloney RM, Alexander GC. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf. 2009;18(11):1094-1100.
4. Healy D. Pharmageddon. Berkeley: University of California Press; 2012.
5. Anderson GM, Juurlink D, Detsky AS. Newly approved does not always mean new and improved. JAMA. 2008;299(13):1598-1600.
6. New Drugs: Grounds for Refusing Application; Approval of Application; "Substantial Evidence" Defined, 21 USC §355d (2010). US Government Printing Office website. http://www.gpo.gov/fdsys/pkg/USCODE-2010- title21/html/USCODE-2010-title21-chap9-subchapV-partA-sec355.htm. Accessed October 7, 2013.
7. US Food and Drug Administration (FDA). Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products. FDA website. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078749.pdf. Accessed October 7, 2013.
8. US Food and Drug Administration (FDA). Guidance for Industry: Non-Inferiority Clinical Trials [Draft Guidance]. FDA website. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM202140.pdf. Accessed October 7, 2013.
9. US Food and Drug Administration (FDA). Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products [Draft Guidance]. FDA website. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf. Accessed October 7, 2013.
10. US Food and Drug Administration (FDA). Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics [Draft Guidance]. FDA website. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM201790.pdf. Accessed October 7, 2013.
11. Booz Allen Hamilton Inc. Independent Evaluation of FDA's First Cycle Review Performance-Final Report. US Food and Drug Administration website. http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm127117.htm. Accessed October 7, 2013.
12. US Food and Drug Administration (FDA). Applications for Food and Drug Administration Approval to Market a New Drug: Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses, 21 CFR §314h (2012). FDA website. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm? CFRPart=314. Accessed October 7, 2013.
13. US Food and Drug Administration (FDA). Drugs@FDA: FDA Approved Drug Products. FDA website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed October 7, 2013.
14. World Health Organization (WHO) Collaborating Center for Drug Statistics Methodology. WHO website. http://www.whocc.no/atc-ddd-index/. 2013. Accessed October 7, 2013.
15. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302(13):1437-1443.
16. Institute of Medicine. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington, DC: National Academies Press; 2010.
17. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887-1892.
18. Smith GCS, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327(7429):1459-1461.
19. Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med. 2011;364(5):476-480.
20. Mitka M. FDA and pharma seek better ways to assess drug safety, efficacy in clinical trials. JAMA. 2012;307(24):2576-2577.
21. US Food and Drug Administration (FDA). Innovative Drug Approvals: 2011 Report. FDA website. http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ ucm330502.htm. Accessed October 7, 2013.
22. US Food and Drug Administration (FDA). FY 2012 Innovative Drug Approvals. FDA website. http://www.fda.gov/AboutFDA/ReportsManuals-Forms/Reports/ ucm276385.htm. Accessed October 7, 2013.
23. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011;305(22):2320-2326.
24. Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ. Availability of comparative efficacy data at the time of drug approval in the United States. JAMA. 2011;305(17):1786-1789.
25. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-613.
26. Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academies Press; 2006.
27. Institute of Medicine. Ethical and Scientific Issues in Studying the Safety of Approved Drugs. Washington, DC: National Academies Press; 2012.
28. Psaty BM, Meslin EM, Breckenridge A. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. JAMA. 2012;307(23):2491-2492.
29. Hamburg MA. Shattuck lecture: innovation, regulation, and the FDA. N Engl J Med. 2010;363(23):2228-2232.
30. Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS. Regulatory review of novel therapeutics-comparison of three regulatory agencies. N Engl J Med. 2012;366(24):2284-2293.
31. Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009;302(24):2679-2685.